Come and meet Rima Ait-Belkacem and Jonathan Stauber to discover all our capabilities. June 4- 8, 2017, in (...)Read more
Webinar on Immuno-Oncology by Rima AIT-BELKACEM, PhD
The webinar titled “Immuno-Oncology: Tryptophan-Kynurenine Microenvironment Tumor Metabolites Pathway Highlighted by (...)Read more
ImaBiotech provides quantitative MALDI Imaging Mass Spectrometry services for quantitative label-free whole body distribution. These services allow the localization and quantification of parent drug and metabolites simultaneously with biomarkers, in more than 25 organs. This represents a cost-effective approach to gain valuable body distribution information, without labeling, from early in drug discovery and lead optimization to late clinical stages; A true addition to the ADMET screening tool box!
Operating in a GLP Environment, ImaBiotech specialists apply extensive, MALDI Imaging Mass Spectrometry expertise to investigate findings in pharmacology and toxicity that may be the results of unexpected localization or accumulation in tissues. They can also address some QWBA limitations, e.g. the ability to distinguish between the parent drug and drug metabolites.
Find out more about the therapeutic areas serviced by ImaBiotech: